Recognition for Gene Synthesis Technology Company

Cambridge-based Evonetix received the award for “Best Emerging Synthetic Biology Company” at the recent Oxford Bioscience Network (OBN) Awards, in recognition of the Company’s novel gene synthesis technology. During its 10th anniversary event held in Oxford towards the end of 2018, OBN reported a record increase in entry numbers, up an impressive 48% on last year’s total. Over 300 delegates attended the event, which recognise and celebrate the most inspiring and innovative UK-based companies across biotech, medtech, imaging, digital and synthetic biology.

By directing the synthesis of DNA at many sites in parallel, followed by an integrated error-detection process throughout assembly, Evonetix’s platform facilitates the synthesis of high-fidelity, long DNA molecules at scale, including challenging sequences with high GC-content or repeats.

CEO Tim Brears, said: “It is a huge honour for our de novo gene synthesis technology to be recognised for its potential impact on the exciting and fast-growing synthetic biology field. At Evonetix we are focused on further advancing our technology to address the need for scale and high fidelity and this accolade is testament to the significant progress we have made.”